Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Cyprium Therapeutics and Sentynl Therapeutics sign Development and Asset Purchase Agreement

Posted On: 2021-02-24 08:14:00 (Time Zone: Arizona, USA)


Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, and Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based specialty pharmaceutical company owned by the Zydus Group, today announced the execution of an asset purchase agreement to commit development funding for and acquire Cyprium's proprietary rights to CUTX-101, its Copper Histidinate product candidate for the treatment of Menkes disease. Under the terms of the agreement, Sentynl will make an upfront cash payment to Cyprium, provide additional cash payments upon the achievement of certain regulatory milestones, and pay royalties and commercial milestone payments based on the net sales of CUTX-101. Cyprium will retain development responsibility of CUTX-101 through approval of the New Drug Application ("NDA") by the U.S. Food and Drug Administration ("FDA"), and Sentynl will be responsible for commercialization of CUTX-101 as well as progressing newborn screening activities. Continued development of CUTX-101 will be overseen by a Joint Steering Committee consisting of representatives from Cyprium and Sentynl.

"We are very pleased to partner with Sentynl to potentially expedite the development and commercialization of CUTX-101. The drug has demonstrated a compelling safety and efficacy profile in topline analysis for the treatment of Menkes disease. We look forward to working with Sentynl to begin the rolling submission of the NDA to the FDA this year. If approved, CUTX-101 will provide a major breakthrough and fill a significant unmet need for children suffering from this rare, fatal pediatric disease," said Lung S. Yam, M.D., Ph.D., President and Chief Executive Officer of Cyprium.

Matt Heck, Co-founder, President & Chief Executive Officer of Sentynl, commented, "Our mission, at the Zydus Group, has been to provide healthcare professionals with access to innovative treatment solutions that enable them to meet the needs of individual patients. We are excited to collaborate with Cyprium in order to broaden our pediatric rare disease portfolio and commercialize CUTX-101, a potentially transformative product, for children with Menkes disease, an unmet healthcare need."

Fortress' Chairman, President and Chief Executive Officer, Lindsay A. Rosenwald, M.D., added, "This transaction with Sentynl further validates the Fortress business model of identifying and developing promising treatments for patients, while pursuing partnership opportunities that potentially maximize shareholder value. We are thrilled with the progress Cyprium has made developing this treatment for Menkes disease and look forward to working with Sentynl to make CUTX-101 available to patients."

Under the agreement, Cyprium is eligible to receive up to $20 million in upfront development and regulatory cash milestones through NDA approval, as well as potential sales milestones. Royalties on CUTX-101 net sales ranging from the mid-single digits up to the mid-twenties are also payable. Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101.

Torreya Partners advised Cyprium on this transaction.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.432.35 as compared to the previous close of Rs. 430.4. The total number of shares traded during the day was 290898 in over 6650 trades.

The stock hit an intraday high of Rs. 438 and intraday low of 412.8. The net turnover during the day was Rs. 124819515.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Other Headlines:

Subex to launch new AI Automation Platform on April 22, 2021

Easy Trip Planners Ltd board declares interim dividend of Rs. 2

Firstsource Solutions Ltd board to consider Q4, FY21 results on May 11, 2021

Happiest Minds wins Times Ascent - World HRD Congress HR Excellence Awards 2021

Indian Energy Exchange commences Cross Border Electricity Trade through its platform

Caplin Steriles gets USFDA approval for Milrinone Lactate Injection

NTPC Ltd declares commercial operation of 85 MW Bilhaur Solar PV Project

G E Shipping takes delivery of a Secondhand Midsize Gas Carrier 'Jag Vikram'

Copenhagen Fintech welcomes Infosys to Elevate Fintech Innovation

Ambuja 'Kawach' recognized globally by Solar Impulse Foundation's efficient solution label

India Ratings assigns Sobha 'IND AA-'/Stable

Sarda Energy & Minerals Ltd updates on Madhya Bharat Power Corporation Ltd

Can Fin Homes Ltd board to consider dividend, Q4, FY21 results on April 30, 2021

HCL to drive end-to-end IT transformation at UD Trucks

WeP Solutions Ltd rights issue to close today

IFGL Refractories Ltd board to consider FY21 results, dividend on May 22, 2021

United Breweries Ltd board to recommend dividend, consider Q4, FY21 results on April 27, 2021

Goa Carbon Limited temporarily shuts down Goa unit for maintenance from April 17, 2021

Sonata Software Ltd board to approve Q4, FY2021 results on May 12, 2021

KPIT Technologies Ltd board to consider dividend, Q4, FY21 results on April 28, 2021

Macrotech Developers Ltd to list on April 19, 2021

KSB Ltd board to approve Q1CY21 results on April 28, 2021

INOX Leisure Limited Ratings downgraded to 'CRISIL A+/Negative/CRISIL A1'

Bhansali Engineering Polymers Ltd Board approves dividend of Rs. 1 for FY21

All Wonderla Amusement Parks will open only on Friday, Saurday and Sunday from April 19, 2021

Bhansali Engineering Polymers Ltd Q4FY21 consolidated PAT jumps to Rs. 163.48 crore

Kalyan Jewellers ushers in the wedding season with its latest Muhurat Campaign

IndusInd Bank Ltd board to consider Q4, FY21 results on April 30, 2021

Jubilant Ingrevia Ltd appoints two directors to its board

Wockhardt Ltd board to consider raising funds through NCDs on April 21, 2021

Trident Ltd celebrating Mission Day with a special discount coupon to shareholders

S.P. Capital Financing Ltd approves selling of shares in Pride And Expert Properties Private Limited

IIFL Securities Limited to acquire Category II AIF from IIFL Wealth Management Ltd

HDFC Bank Limited to raise up to Rs. 50,000 crore

Indo Asian Finance Ltd to consider allotment of 60 lakh shares on April 20, 2021

KEC International Limited Resumption of WKTL Transmission Project

IIFL Wealth Management Ltd to sell AIF Category-II business to IIFL Management Services Ltd

International Travel House Ltd Q4FY21 loss at Rs. 6.70 crore

Gujarat Hotels Ltd Q4FY21 net profit slides YoY, QoQ

ICICI Lombard General Insurance Company Limited board recommends final dividend of Rs. 4

Gujarat Hotels Ltd board recommends dividend of Rs. 1.80 for FY21

ICICI Lombard General Insurance Company Ltd reports Rs. 345.68 crore PAT in Q4FY21

HDFC Bank Ltd's gross NPAs at 1.32%, reduces QoQ

HDB Financial Services Ltd's gross NPAs at 3.9% as of March 31, 2021

HDFC Securities Ltd reports PAT of Rs. 253.1 crore in Q4FY21

Career Point signed MOU with Ministry of Social Justice and Empowerment for tutorial services

HDFC Bank's balance sheet increases 14.1% YoY

Indiamart arm to acquire 22% in Truckhall Pvt Ltd

HDFC Bank Ltd Q4FY21 consolidated net profit slips QoQ to Rs. 8433.78 crore

CRISIL downgrades rating of PVR Ltd


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020